| Project/Area Number |
25462328
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
MATSUBARA TAKAO 三重大学, 医学(系)研究科(研究院), 講師 (30422827)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUMINE AKIHIKO 三重大学, 医学系研究科, 准教授 (00335118)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 放射線耐性 / アクリジンオレンジ療法 / 低酸素耐性 / CA9 / 低酸素環境 / 悪性腫瘍 / 抗がん剤耐性 / アクリジンオレンジ光線療法 / 放射線力学的療法 / アクリジンオレンジ / 光線力学的療法 |
|---|
| Outline of Final Research Achievements |
Acridine orange （AO） which is a photosensitizer accumulated to human osteosarcoma, lung cancer and breast cancer cell lines under the tumor microenvironmental condition (acidic, low oxygen and high hydrostatic pressure). There was amplification effect of about 1.5-2 times by changing tumor microenvironment, and, it was confirmed to have a higher cytotoxic effect against tumors in such specific condition. In the study of AO therapy for registrant strains. AO have a good citocydal effect for registrant strains, but there was no amplication effect in combination with AO and the protein obtained gene expression due to the tumor-specific extracellular environment analysis. While we revealed that CA9 is one of good target for osteosarcoma therapy, and that CA9 inhibitor suppressed the invasiveness and metastatic potential. In future, combination with CA9 and anti-tumor therapy can control local tumor recurrence and metastatic potential for sarcoma patients.
|
